Search hospitals > Kansas > Lawrence
Lawrence Memorial Hospital
Claim this profileLawrence, Kansas 66044
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
395 reported clinical trials
23 medical researchers
Summary
Lawrence Memorial Hospital is a medical facility located in Lawrence, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Lawrence Memorial Hospital is involved with conducting 395 clinical trials across 505 conditions. There are 23 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Jun Zhang, Gary C. Doolittle, and Chao H. Huang.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Shaker Dakhil, M.D.Cancer Center of Kansas - Wichita5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
81 reported clinical trials
168 drugs studied
Jun ZhangHouston Methodist Hospital4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
25 reported clinical trials
40 drugs studied
Gary C. DoolittleHaysMed University of Kansas Health System3 years of reported clinical research
Studies Cancer
Studies Melanoma
18 reported clinical trials
29 drugs studied
Chao H. HuangUniversity of Kansas Health System Saint Francis Campus5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
19 reported clinical trials
31 drugs studied
Clinical Trials running at Lawrence Memorial Hospital
Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Bladder Cancer
Bladder Carcinoma
Urothelial Carcinoma
Renal Cell Carcinoma
Squamous Cell Carcinoma
Tumors
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Lawrence Memorial Hospital?
Lawrence Memorial Hospital is a medical facility located in Lawrence, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Lawrence Memorial Hospital is involved with conducting 395 clinical trials across 505 conditions. There are 23 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Jun Zhang, Gary C. Doolittle, and Chao H. Huang.
Where is Lawrence Memorial Hospital located?
**Lawrence Memorial Hospital**
- **Address:** 325 Maine Street, Lawrence, KS 66044
- **Location:** Approximately 2 miles from downtown Lawrence, near the intersection of Maine Street and 6th Street.
Who should I call to ask about financial aid or insurance network?
**Lawrence Memorial Hospital Financial Assistance**
- For financial assistance, including charity care, payment arrangements, and medical assistance programs, please contact our financial counselor at 785-505-5775.
- Application forms and further information are available through the financial counselor.
What insurance does Lawrence Memorial Hospital accept?
Lawrence Memorial Hospital accepts Blue Cross and Blue Shield of Kansas (BCBSKS) insurance plans. The hospital participates with most major managed care and governmental health insurance plans in the Northeast, including Medicaid and Medicare. Patients should contact their health insurance company directly to confirm specific plan and benefit coverage, as participation with health plans does not guarantee coverage.
What awards or recognition has Lawrence Memorial Hospital received?
**Lawrence Memorial Hospital, Lawrence, Kansas**
- Recognized as one of the 100 Top Hospitals by Truven Health Analytics.
- Received a $2 million grant from the Sunderland Foundation for support.